Vaccines After CAR-T Infusion: Effectiveness and Timing
Vaccines are effective after CAR-T infusion, but responses are significantly impaired, particularly for antibody production—however, vaccination should still be administered because cellular T-cell immunity can provide meaningful protection even when antibody responses fail. 1, 2
Key Evidence on Vaccine Effectiveness
Humoral (Antibody) Response Rates
The effectiveness varies substantially by vaccine type and timing:
- COVID-19 vaccines: Only 28-35% of CAR-T recipients develop antibody responses, but critically, up to 72% develop protective cellular T-cell responses 2
- Influenza vaccines: Approximately 31% achieve adequate antibody responses (≥4-fold titer increase) when vaccinated 13-57 months post-CAR-T 2, 3
- Other inactivated vaccines: Response rates at 20 months post-CAR-T show antibody levels comparable to general population for most antigens, except pneumococcus, Haemophilus influenzae type b, pertussis (0-15%), and hepatitis B (39%) 2
Critical Finding: T-Cell Responses Compensate for Poor Antibody Production
The most important clinical insight is that functional T-cell responses occur even in patients with B-cell aplasia and absent antibody responses 4, 5. This means vaccination provides benefit through cellular immunity when humoral immunity fails—a crucial distinction for CAR-T recipients.
Recommended Vaccination Timeline
Inactivated/Killed Vaccines
Influenza and COVID-19 vaccines:
- Optimal timing: ≥3 months post-CAR-T infusion 1
- Can vaccinate despite ongoing immunosuppression
- Should be given irrespective of B-cell aplasia status
- Consider booster doses upon B-cell recovery
Other inactivated vaccines (pneumococcal, hepatitis, etc.):
- Minimum timing: ≥6 months post-CAR-T 1
- Must be >2 months after last immunoglobulin replacement
- Contraindications: Concurrent immunosuppressive or cytotoxic therapy
Live and Adjuvanted Vaccines
Strict requirements 1:
- Minimum timing: 1 year post-CAR-T
- Must have complete immune reconstitution documented
- Additional contraindications:
- <2 years post-allogeneic HCT (if applicable)
- <8 months after completion of IVIG therapy
Factors Predicting Vaccine Response
Better responses occur with:
- Multiple myeloma (BCMA-targeted CAR-T) vs. non-Hodgkin lymphoma (CD19-targeted) 2, 6
- Higher baseline CD19+ B-cell counts (>0.2 × 10⁹/L) 1
- Higher pre-vaccination IgA levels 7
- Absolute B-cell counts trending higher 7
- Four or more vaccine doses for COVID-19 (OR 8.22) 6
Poorer responses associated with:
- Prolonged B-cell aplasia
- Severe hypogammaglobulinemia
- Multiple prior lines of therapy
- Advanced age
- Concurrent cytopenias 2
Clinical Algorithm for Post-CAR-T Vaccination
Month 3 post-CAR-T:
- Initiate influenza vaccine (if in season)
- Initiate COVID-19 vaccine series
- Vaccinate regardless of B-cell counts or immunoglobulin levels
Month 6 post-CAR-T:
- Begin other inactivated vaccines (pneumococcal, hepatitis A/B, Tdap, meningococcal)
- Ensure >2 months since last IVIG
- Hold if on active immunosuppression
Month 12 post-CAR-T:
- Assess immune reconstitution (CD4 >0.2 × 10⁹/L, CD19/CD20 B cells >0.2 × 10⁹/L)
- If fully reconstituted and no immunosuppression for 8+ months: consider live vaccines (MMR, varicella)
- If prior allo-HCT: wait until 2 years post-transplant
Ongoing monitoring:
- Consider post-vaccination antibody titer monitoring 1
- Administer booster doses upon B-cell recovery
- Continue seasonal influenza vaccination annually
Critical Caveats
Don't withhold vaccination due to B-cell aplasia: The 2024 ASCO guidelines emphasize that B-cell aplasia is NOT a contraindication because T-cell-mediated immunity remains functional 2
Multiple doses improve responses: For COVID-19, ≥4 vaccine doses significantly improve seroconversion (OR 8.22), supporting repeated vaccination strategies 6
Early vaccination (<4 months) is not harmful: Recent data show no impairment of functional T-cell responses when vaccinating early post-CAR-T 4
Heterogeneity exists: Response varies by CAR-T target (CD19 vs. BCMA vs. CD20), underlying disease, and individual immune reconstitution 2, 7
Pre-CAR-T vaccination is superior: Whenever possible, vaccinate 2 weeks before lymphodepletion—responses are better and can persist post-CAR-T 1, 5
The evidence strongly supports vaccination after CAR-T despite impaired responses, as the reduction in infection rates and improved clinical outcomes justify vaccination even with suboptimal antibody production.